AstraZeneca SCLC Webinar
Webinar Overview: Challenges in Treating Patients with Small Cell Lung Cancer (SCLC) – Durvalumab as a Therapeutic Option
AstraZeneca is hosting a webinar focused on the challenges of treating Small Cell Lung Cancer (SCLC), a highly aggressive cancer type. The session will delve into the complexities of SCLC management, highlighting the critical need for innovative treatment approaches. A key point of discussion will be the role of Durvalumab, an immune checkpoint inhibitor, as a therapeutic option. Experts will share insights into the latest clinical trials, efficacy data, and practical considerations for integrating Durvalumab into treatment regimens. The webinar aims to provide healthcare professionals with up-to-date knowledge to enhance patient outcomes in SCLC treatment.
Planning and coordinating the event’s agenda, securing expert speakers, managing the technical aspects of the webinar platform. Promotional activities, creating marketing materials and outreach to target audiences. Management of participant registration, providing technical support during the event, ensuring smooth execution. Post-event tasks include collecting feedback, distributing recorded sessions, and analyzing engagement metrics.
Improving health is one of the greatest challenges the world faces today.
As a global innovative biopharmaceutical company, AstraZeneca plays a crucial role in discovering, developing, and distributing innovative medicines in key areas of healthcare, including cardiovascular, renal, and metabolic diseases, respiratory diseases, inflammatory and autoimmune disorders, and oncology. The company was established in 1999 through the merger of Sweden’s Astra AB and the UK’s Zeneca Group, becoming one of the largest pharmaceutical companies in the world. It has since made numerous corporate acquisitions, including Cambridge Antibody Technology (2006), MedImmune (2007), Spirogen (2013), and Definiens (MedImmune 2014).
In Serbia, AstraZeneca focuses on the following therapeutic areas: cardiovascular, renal, and metabolic diseases, oncology, and respiratory diseases and immunology.
